Irinotecan in Treating Patients With Advanced Solid Tumors
NCT00004051
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG:
irinotecan hydrochloride
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
[object Object]